Skip to content

Impact of Ondansetron on withdrawal syndrome and fentanyl requirement in opium addicted patients under general anesthesia.

Impact of Ondansetron on withdrawal syndrome and fentanyl requirement in opium addicted patients under general anesthesia.

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT2017051333940N1
Enrollment
96
Registered
2017-07-17
Start date
2017-05-22
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Addicted patients with opioid dependence. Mental and behavioural disorders due to use of opioids

Interventions

Intervention 1: Biography of included patients is registered and distributed in one of the study groups, and to each group of these patients, different doses of 4 mg and 8 mg of andestron are injected
Treatment - Drugs
Biography of included patients is registered and distributed in one of the study groups, and to each group of these patients, different doses of 4 mg and 8 mg of andestron are injected intravenously 1
The control group received all the conditions for the treatment group with ondansetrone, except that they received a placebo containing 2 ml of distilled water, which is injected intravenously 15 minu

Sponsors

Pharmaceutical Research Center, Faculty of Pharmacy
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
19 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: patients addicted to opiates in the age range of 19-70 years and have fractures. Exclusion criteria:addicted patients who have multi-drug use together or surgery prolongation or induction and maintenance of anesthesia with other Protocol that fentanyl not included.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Withdrawal signs and pain. Timepoint: Up to 2h after ondansetron ijjection. Method of measurement: Observation.;Withdrawal signs and pain. Timepoint: Visual analogue scale. Method of measurement: Up to 2h after injection of ondansetron.

Secondary

MeasureTime frame
Pain. Timepoint: Up to 2h after ondansetron injection. Method of measurement: Observation.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHamid Reza Rahimi

Kerman Faculty of Pharmacy

h_rahimi@kmu.ac.irhamidrrt@yahoo.com+98 34 3132 5437

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026